Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab

BACKGROUND: Antibody-drug conjugates (ADC) are essential therapeutic options to treat solid and hematological cancers. The anti-epidermal growth factor-receptor (EGFR) antibody cetuximab (Cet) is used for the therapy of colorectal carcinoma (CRC). Anti-CRC Vδ2 cytolytic T lymphocytes can be elicited...

Descripción completa

Detalles Bibliográficos
Autores principales: Benelli, Roberto, Costa, Delfina, Salvini, Laura, Tardito, Samuele, Tosetti, Francesca, Villa, Federico, Zocchi, Maria Raffaella, Poggi, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772689/
https://www.ncbi.nlm.nih.gov/pubmed/36543375
http://dx.doi.org/10.1136/jitc-2022-005660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772689/
https://www.ncbi.nlm.nih.gov/pubmed/36543375
http://dx.doi.org/10.1136/jitc-2022-005660

Ejemplares similares